Analysts expect that Edesa Biotech, Inc. (NASDAQ:EDSA – Get Rating) will report earnings of ($0.37) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Edesa Biotech’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.41). Edesa Biotech reported earnings per share of ($0.19) in the same quarter last year, which would indicate a negative year over year growth rate of 94.7%. The company is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Edesa Biotech will report full year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.57) to ($1.15). For the next fiscal year, analysts forecast that the company will report earnings of $0.97 per share, with EPS estimates ranging from ($1.42) to $5.26. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Edesa Biotech.
Edesa Biotech (NASDAQ:EDSA – Get Rating) last announced its quarterly earnings results on Monday, February 14th. The company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.07.
Shares of Edesa Biotech stock traded up $0.04 during trading hours on Monday, hitting $2.22. The company’s stock had a trading volume of 50,441 shares, compared to its average volume of 59,085. The firm has a fifty day moving average of $3.02 and a 200-day moving average of $4.89. Edesa Biotech has a twelve month low of $2.07 and a twelve month high of $12.00.
About Edesa Biotech (Get Rating)
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis.
- Get a free copy of the StockNews.com research report on Edesa Biotech (EDSA)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.